Kurs & Likviditet
Beskrivning
| Land | Storbritannien |
|---|---|
| Lista | Large Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Kalender
| 2021-11-12 | Kvartalsrapport 2021-Q3 |
| 2021-07-29 | Kvartalsrapport 2021-Q2 |
| 2021-04-30 | Kvartalsrapport 2021-Q1 |
| 2021-02-25 | Halvårsutdelning AZN 15.76 |
| 2021-02-11 | Bokslutskommuniké 2020 |
| 2020-11-05 | Kvartalsrapport 2020-Q3 |
| 2020-08-13 | Halvårsutdelning AZN 7.87 |
| 2020-07-30 | Kvartalsrapport 2020-Q2 |
| 2020-04-29 | Kvartalsrapport 2020-Q1 |
| 2020-04-29 | Årsstämma 2020 |
| 2020-02-27 | Halvårsutdelning AZN 18.32 |
| 2020-02-14 | Bokslutskommuniké 2019 |
| 2019-08-08 | Halvårsutdelning AZN 8.49 |
| 2019-04-26 | Årsstämma 2019 |
| 2019-02-28 | Halvårsutdelning AZN 17.46 |
| 2019-02-14 | Bokslutskommuniké 2018 |
| 2018-11-08 | Kvartalsrapport 2018-Q3 |
| 2018-08-09 | Halvårsutdelning AZN 7.92 |
| 2018-07-26 | Kvartalsrapport 2018-Q2 |
| 2018-05-18 | Kvartalsrapport 2018-Q1 |
| 2018-05-18 | Årsstämma 2018 |
| 2018-02-15 | Halvårsutdelning AZN 14.97 |
| 2018-02-02 | Bokslutskommuniké 2017 |
| 2017-11-09 | Kvartalsrapport 2017-Q3 |
| 2017-08-10 | Halvårsutdelning AZN 7.4 |
| 2017-07-27 | Kvartalsrapport 2017-Q2 |
| 2017-04-27 | Årsstämma 2017 |
| 2017-04-27 | Kvartalsrapport 2017-Q1 |
| 2017-02-16 | Halvårsutdelning AZN 16.57 |
| 2017-02-02 | Bokslutskommuniké 2016 |
| 2016-11-10 | Kvartalsrapport 2016-Q3 |
| 2016-08-11 | Halvårsutdelning AZN 7.81 |
| 2016-07-28 | Kvartalsrapport 2016-Q2 |
| 2016-04-29 | Årsstämma 2016 |
| 2016-04-29 | Kvartalsrapport 2016-Q1 |
| 2016-02-18 | Halvårsutdelning AZN 16.26 |
| 2016-02-04 | Bokslutskommuniké 2015 |
| 2015-11-05 | Kvartalsrapport 2015-Q3 |
| 2015-08-13 | Halvårsutdelning AZN 7.71 |
| 2015-07-30 | Kvartalsrapport 2015-Q2 |
| 2015-04-24 | Årsstämma 2015 |
| 2015-04-24 | Kvartalsrapport 2015-Q1 |
| 2015-02-19 | Halvårsutdelning AZN 15.62 |
| 2015-02-05 | Bokslutskommuniké 2014 |
| 2014-11-06 | Kvartalsrapport 2014-Q3 |
| 2014-08-13 | Halvårsutdelning AZN 6.2 |
| 2014-07-31 | Kvartalsrapport 2014-Q2 |
| 2014-04-24 | Kvartalsrapport 2014-Q1 |
| 2014-04-24 | Årsstämma 2014 |
| 2014-02-19 | Halvårsutdelning AZN 12.41 |
| 2014-02-06 | Bokslutskommuniké 2013 |
| 2013-10-31 | Kvartalsrapport 2013-Q3 |
| 2013-08-14 | Halvårsutdelning AZN 5.92 |
| 2013-08-01 | Analytiker möte 2013 |
| 2013-08-01 | Kvartalsrapport 2013-Q2 |
| 2013-04-25 | Kvartalsrapport 2013-Q1 |
| 2013-04-25 | Årsstämma 2013 |
| 2013-02-13 | Halvårsutdelning AZN 12.08 |
| 2013-01-31 | Bokslutskommuniké 2012 |
| 2012-10-25 | Kvartalsrapport 2012-Q3 |
| 2012-10-25 | Analytiker möte 2012 |
| 2012-08-08 | Halvårsutdelning AZN 6.26 |
| 2012-07-26 | Kvartalsrapport 2012-Q2 |
| 2012-04-26 | Kvartalsrapport 2012-Q1 |
| 2012-04-26 | Årsstämma 2012 |
| 2012-02-15 | Halvårsutdelning AZN 13.21 |
| 2012-02-02 | Bokslutskommuniké 2011 |
| 2011-10-27 | Kvartalsrapport 2011-Q3 |
| 2011-08-03 | Halvårsutdelning AZN 5.33 |
| 2011-07-28 | Kvartalsrapport 2011-Q2 |
| 2011-04-28 | Kvartalsrapport 2011-Q1 |
| 2011-04-28 | Årsstämma 2011 |
| 2011-02-02 | Halvårsutdelning AZN 11.99 |
| 2011-01-27 | Bokslutskommuniké 2010 |
| 2010-10-28 | Kvartalsrapport 2010-Q3 |
| 2010-08-04 | Halvårsutdelning AZN 5.12 |
| 2010-07-29 | Kvartalsrapport 2010-Q2 |
| 2010-04-29 | Kvartalsrapport 2010-Q1 |
| 2010-02-03 | Halvårsutdelning AZN 12.43 |
| 2010-01-28 | Bokslutskommuniké 2009 |
| 2009-10-29 | Kvartalsrapport 2009-Q3 |
| 2009-08-05 | Halvårsutdelning AZN 4.41 |
| 2009-07-30 | Kvartalsrapport 2009-Q2 |
| 2009-04-30 | Årsstämma 1 |
| 2009-04-30 | Kvartalsrapport 2009-Q1 |
| 2009-02-04 | Halvårsutdelning AZN 12.02 |
| 2008-08-06 | Halvårsutdelning AZN 3.34 |
| 2008-02-06 | Halvårsutdelning AZN 8.61 |
| 2007-08-08 | Halvårsutdelning AZN 3.49 |
| 2007-02-07 | Halvårsutdelning AZN 8.6 |
| 2006-08-09 | Halvårsutdelning AZN 3.6 |
| 2006-02-08 | Halvårsutdelning AZN 7.02 |
| 2005-08-10 | Halvårsutdelning AZN 2.99 |
| 2005-02-09 | Halvårsutdelning AZN 4.497 |
| 2004-08-11 | Halvårsutdelning AZN 2.2 |
| 2004-02-18 | Halvårsutdelning AZN 3.91 |
| 2003-08-20 | Halvårsutdelning AZN 2.07 |
| 2003-02-19 | Halvårsutdelning AZN 3.99 |
| 2002-08-21 | Halvårsutdelning AZN 2.21 |
| 2002-02-20 | Halvårsutdelning AZN 5.01 |
| 2001-08-22 | Halvårsutdelning AZN 2.44 |
| 2001-02-21 | Halvårsutdelning AZN 4.49 |
| 2000-09-04 | Halvårsutdelning AZN 2.1 |
| 2000-03-08 | Halvårsutdelning AZN 4.01 |
| 1999-09-06 | Halvårsutdelning AZN 1.89 |
| 1999-04-01 | Split AZN 1:0.5045 |
| 1997-05-26 | Split AZN 1:2 |
| 1993-06-14 | Split AZN 1:5 |
| 1987-06-04 | Split AZN 1:2 |
AstraZeneca has completed the divestment of the rights to Crestor (https://www.astrazeneca.com/media-centre/press-releases/2020/crestor-to-be-divested-to-grunenthal-in-europe.html) (rosuvastatin) and associated medicines in over 30 countries in Europe to Grünenthal GmbH (Grünenthal). Rights in the UK and Spain were not included in the agreement.
Financial considerations
Under the terms of the agreement, AstraZeneca received a payment of $320m from Grünenthal and may also be eligible for future milestone payments of up to $30m. The upfront payment will be reported in AstraZeneca's financial statements within other operating income and expense in the first quarter of 2021.
Pursuant to London Stock Exchange listing rule 10.4.1R (notification of class 2 transactions), the gross book value of assets subject to the divestment as of 31 December 2019 was $nil. In 2019, Crestor generated product sales of $136m and profit before tax of $98m in the countries covered by the agreement. The consideration was and will be paid in cash and the proceeds used for general corporate purposes.
Crestor
Crestor (rosuvastatin) is a statin, a lipid-lowering medicine, used to treat blood lipid disorders and to prevent cardiovascular events, such as heart attacks and strokes. Crestor produces its lipid-modifying effects in two ways: it blocks an enzyme in the liver, causing the liver to make less cholesterol, and it increases the uptake and breakdown by the liver of cholesterol already in the blood. Crestor is approved as a lipid-regulating medicine in more than 100 countries.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the Company on Twitter @AstraZeneca (https://twitter.com/AstraZeneca).
Contacts
For details on how to contact the Investor Relations Team, please click here (https://www.astrazeneca.com/investor-relations.html#Contacts). For Media contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html).